---
title: "Salubris: The clinical trial application for the self-developed innovative small molecule drug SAL0140 tablets has been accepted"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/254948638.md"
description: "Salubris announced that its self-developed small molecule drug SAL0140 tablet's clinical trial application has been accepted by the National Medical Products Administration. SAL0140 is an aldosterone synthase inhibitor, primarily targeting indications such as uncontrolled hypertension and chronic kidney disease. Currently, the drug is in the Phase I clinical stage, and if successfully developed and approved, it will provide new treatment options for relevant patients, meeting clinical needs"
datetime: "2025-08-28T08:13:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/254948638.md)
  - [en](https://longbridge.com/en/news/254948638.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/254948638.md)
generator: "portal-rs"
---

# Salubris: The clinical trial application for the self-developed innovative small molecule drug SAL0140 tablets has been accepted

According to the Zhitong Finance APP, Salubris (002294.SZ) announced that it has recently received the acceptance notice issued by the National Medical Products Administration. The clinical trial application for the company's independently developed innovative small molecule drug SAL0140 tablets (project code: SAL0140) has been accepted.

SAL0140 is an aldosterone synthase inhibitor with independent intellectual property rights, intended to develop indications including uncontrolled hypertension (including resistant hypertension) and chronic kidney disease (CKD). Currently, SAL0140 (uncontrolled hypertension) is in the Phase I clinical stage.

If SAL0140 can be successfully developed and approved for marketing, it is expected to provide targeted new medication options for more patients with hypertension and CKD in specific subfields, meeting unmet clinical needs and further enriching the company's innovative product pipeline in the chronic disease field

### Related Stocks

- [002294.CN](https://longbridge.com/en/quote/002294.CN.md)

## Related News & Research

- [Vishnusurya Projects and Infra's (NSE:VISHNUINFR) Weak Earnings May Only Reveal A Part Of The Whole Picture](https://longbridge.com/en/news/305559929.md)
- [Pondy Oxides And Chemicals Limited Just Missed Earnings And Its Revenue Numbers Were Weaker Than Expected](https://longbridge.com/en/news/305560101.md)
- [Alkem Laboratories Limited (NSE:ALKEM) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates](https://longbridge.com/en/news/305559747.md)
- [RioCan Real Estate Investment Trust (TSX:REI.UN) Expands Its Buyback Program, Is It Still Undervalued?](https://longbridge.com/en/news/305557624.md)
- [Kava Lend loses roughly $3.8 million to hack, sending KAVA token down nearly 40%](https://longbridge.com/en/news/305556359.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**